U 76807
Latest Information Update: 06 Oct 1997
At a glance
- Originator Pharmacia Corporation
- Class Antihyperlipidaemics
- Mechanism of Action Sterol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 06 Oct 1997 No-Development-Reported for Hyperlipidaemia in USA (Unknown route)